Q&M Dental Group announced on September 15, that its 51%-owned subsidiary Acumen Diagnostics has obtained the Healthcare Institution License issued by the Ministry of Health to offer clinical laboratory testing services for the SARS CoV-2 RNA.
Acumen will use its proprietary SARS CoV-2 RT-PCR test kit, Acu-Corona 2.0 to provide testing services. The test kit received Singapore Health Sciences Authority’s (HSA) Provisional Authorisation for clinical use in March 2020.
The Acu-Corona 2.0 test, which is based on detecting two genes of the Covid-19 virus, Rdrp and E, has been independently validated through the Proficiency Testing program for SARS CoV-2 implemented by College of American Pathologists (CAP).
Q&M Dental Group, through its wholly-owned subsidiary Acumen Diagnostics entered into a proposed joint venture with Acumen Research Laboratories in April to acquire the parts that deal with the manufacture, sale, and distribution of Covid-19 diagnostic test kits and vaccines.
Shares in Q&M closed 0.5 cent lower, or 1.1% down, at 47 cents on September 16.
